Asset Details
Do you wish to reserve the book?
Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting
Do you wish to request the book?
Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting
2009
Overview
Goals of work
Ginger has been used to treat numerous types of nausea and vomiting. Ginger has also been studied for its efficacy for acute chemotherapy-induced nausea and vomiting (CINV). However, its efficacy for delayed CINV in a diverse oncology population is unknown.
Materials and methods
We performed a randomized, double-blind, placebo-controlled trial in 162 patients with cancer who were receiving chemotherapy and had experienced CINV during at least one previous round of chemotherapy. All participants were receiving a 5-HT
3
receptor antagonists and/or aprepitant. Participants were randomized to receive either 1.0 g ginger, 2.0 g ginger daily, or matching placebo for 3 days. The primary outcome was change in the prevalence of delayed CINV. Secondary outcomes included acute prevalence of CINV, acute and delayed severity of CINV, and assessment of blinding.
Main results
There were no differences between groups in the prevalence of delayed nausea or vomiting, prevalence of acute CINV, or severity of delayed vomiting or acute nausea and vomiting. Participants who took both ginger and aprepitant had more severe acute nausea than participants who took only aprepitant. Participants were able to accurately guess which treatment they had received. Ginger appeared well tolerated, with no difference in all adverse events (AEs) and significantly less fatigue and miscellaneous AEs in the ginger group.
Conclusions
Ginger provides no additional benefit for reduction of the prevalence or severity of acute or delayed CINV when given with 5-HT
3
receptor antagonists and/or aprepitant.
Publisher
Springer-Verlag,Springer Nature B.V
Subject
/ Aged
/ Antiemetics - administration & dosage
/ Antiemetics - adverse effects
/ Antiemetics - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Cancer
/ Delayed
/ Dose-Response Relationship, Drug
/ Efficacy
/ Female
/ Humans
/ Male
/ Medicine
/ Morpholines - therapeutic use
/ Nausea
/ Nursing
/ Oncology
/ Patients
/ Serotonin 5-HT3 Receptor Antagonists
/ Serotonin Antagonists - therapeutic use
/ Severity
/ Vomiting
Seems like something went wrong :( Kindly try again later!